Bristol Myers Squibb (NYSE: BMY) today announced the U.S. Food and Drug Administration (FDA) accepted a supplemental New Drug Application (sNDA) for Camzyos (mavacamten) as a pote ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results